Transcript Future - Sveikatos Forumas

Science meets reality
Richard BERGSTRÖM
Director General EFPIA
Agenda
• The new science
– Understanding of disease
– Collaboration – big time
• The real world
– Budgets
– Ineffeciencies
– Access
• The way forward
2
Translational medicine
Our
missing
link
The world of the patients
(and the Doctors, caregivers
and Health care systems)
The molecular world
A world of diseases typically
based on subjective
definitions
A world of diseases
defined by objective molecular
parameters
3/x
Future medicine is targeted
Patients as we see them
today
Biology x
Biology y
Biology z
What
treatment
is right
for me?
Patients as we see them
tomorrow
Future medicine
Today
Today we diagnose and
treat based on symptoms
and a subjective
interpretation of
symptoms
Future
In the future we diagnose
and treat based on
biology and select
medication based on an
objective evaluation of
the benefit/risk for the
individual patient
5/x
Parkinson’s disease
Today:
Future:
Parkin
(10-20%)
Parkinson’s
LRRK2
(5-10%)
a-Synuclein
(<0.5%)
Clinically descriptive
approach:
- Motor function
- Cognition
- Psychiatric symptoms
Decision to treatment
PINK1
(1-7%)
DJ1
(1-2%)
Defined patient groups,
each linked to specific
genetic defects
Specific
treatment for
each group
Some specific
treatments might
provide benefit for
broader PD patient
groups
The European Union and the
pharmaceutical industry
have joined forces to make
drug R&D processes in Europe
more
efficient and effective
and enhance Europe’s
competitiveness in the sector.
The reality…
Differences in access
IMS Health, 2010
Source: Innovation and Solidarity in Pharmaceuticals,EU Belgian Presidency Ministerial Conference, 09/2010
Exploiting efficiency gains would allow to
improve health outcomes further
Gains in life expectancy, years
6
increase over 1997-2007
5
4
3
2
1
0
Source: OECD Health Data 2009; OECD calculations.
Potential gains in 2007 through greater efficiency
Exploiting efficiency gains would help
to contain future spending
140
% increase in per capita spending, in real terms
1997-2007
120
100
80
60
40
20
0
Source: OECD Health Data 2009; OECD calculations.
2007-2017, if exploiting efficiency gains
Cost due to mix and price
in six therapeutic areas
1.00
Average cost per treatment day, €
0.90
Q2 2011
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
SOURCE: IMS MIDAS Q2 2011
SIX THERAPY CLASSES: A2B Antiulcerants, C10A Cholesterol and triglyceride reducers, C9C Angiotensin II antagonists, N3A Antiepileptic, N5A
Antipsychotics, N6A Antidepressants. Source: IMS MIDAS, Q2 2011
12
Way forward
• Be ready for the new science
• Health is wealth – an investment
• Take out waste, look for efficiency
• We are all in this together
13
Thank you!